Lurbinectedin is primarily used in the treatment of metastatic small cell lung cancer (SCLC) in patients who have experienced disease progression after platinum-based chemotherapy. It works by inhibiting transcription and inducing DNA breaks, leading to apoptosis in cancer cells. This drug offers a therapeutic option for patients with limited treatment alternatives, improving progression-free survival and overall response rates. It is administered intravenously under medical supervision, often as part of a carefully monitored treatment regimen. Ongoing research is exploring its potential efficacy in other types of cancers, including ovarian and breast cancer.